BRM.XETRA Bristol-Myers Squibb Company

Healthcare Pharmaceuticals XETRA Stock Exchange
56.92 EUR
Close of Nov 5, 2026
37.49 60.56
Market cap
EUR 116B
P/E
14.7x
P/B
5.49x
ROE
46.7%
Dividend yield
4.04%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BRM.XETRA undervalued?

Graham number
Price56.92
Graham value30.09
Premium89.2%

BRM.XETRA trades 89.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bristol-Myers Squibb Company fundamental analysis

No fundamental analysis for Bristol-Myers Squibb Company yet.

Bristol-Myers Squibb Company stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresecta…

Full company profile